Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Insights From the Department of Veterans Affairs

Salim S. Virani*, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J Stone, Laura A. Petersen, Christie M. Ballantyne

*Corresponding author for this work

Research output: Contribution to journalLetter

4 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)410-412
Number of pages3
JournalCirculation
Volume139
Issue number3
DOIs
StatePublished - Jan 15 2019

Fingerprint

Veterans
Cholesterol
Clinical Trials
Costs and Cost Analysis
Proprotein Convertase 9

Keywords

  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Virani, Salim S. ; Akeroyd, Julia M. ; Nambi, Vijay ; Michos, Erin D. ; Morris, Pamela B. ; Nasir, Khurram ; Smith, Sidney C. ; Stone, Neil J ; Petersen, Laura A. ; Ballantyne, Christie M. / Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial : Insights From the Department of Veterans Affairs. In: Circulation. 2019 ; Vol. 139, No. 3. pp. 410-412.
@article{ece5249b61f646eb8b722bdbf701883a,
title = "Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs",
keywords = "cholesterol, clinical trial",
author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Vijay Nambi and Michos, {Erin D.} and Morris, {Pamela B.} and Khurram Nasir and Smith, {Sidney C.} and Stone, {Neil J} and Petersen, {Laura A.} and Ballantyne, {Christie M.}",
year = "2019",
month = "1",
day = "15",
doi = "10.1161/CIRCULATIONAHA.118.034993",
language = "English (US)",
volume = "139",
pages = "410--412",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial : Insights From the Department of Veterans Affairs. / Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay; Michos, Erin D.; Morris, Pamela B.; Nasir, Khurram; Smith, Sidney C.; Stone, Neil J; Petersen, Laura A.; Ballantyne, Christie M.

In: Circulation, Vol. 139, No. 3, 15.01.2019, p. 410-412.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

T2 - Insights From the Department of Veterans Affairs

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Michos, Erin D.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Smith, Sidney C.

AU - Stone, Neil J

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

PY - 2019/1/15

Y1 - 2019/1/15

KW - cholesterol

KW - clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85060035929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060035929&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.034993

DO - 10.1161/CIRCULATIONAHA.118.034993

M3 - Letter

VL - 139

SP - 410

EP - 412

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -